ArticleClinicoEconomics and outcomes research : CEOR2026
Economic-Clinical Burdens of Tuberculosis Treatment in Vulnerable Patients in a Provincial General Referral Hospital in Lubumbashi, DR Congo.
Article in ClinicoEconomics and outcomes research : CEOR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: According to an analysis of the catastrophic costs incurred by people with tuberculosis, 56% of households in the Democratic Republic of Congo bear the economic burden of tuberculosis. The objective of this study was to determine the clinical and economic burdens of tuberculosis treatment in vulnerable patients. Methods: A descriptive, cross-sectional study was conducted at Janson Sendwe Provincial General Referral Hospital between September and December 2023, a four-month period. Data collection was based on a previously developed survey form with several parameters. Results: In this study, 59 tuberculosis cases with vulnerability factors were recorded. Male sex was the most prevalent with 62.71%, the average patient age was 33.37 ± 9.92 (15-68) years, TB/HIV coinfection was the most prominent with 94.92%, the average total cost was 56.74 ± 20.81 USD, direct costs were 10.61 ± 0.00 and indirect costs were 47.75 ± 19.23 USD. The average direct costs were 1.56 ± 0.19 USD. Conclusion: Catastrophic costs for tuberculosis patients can be addressed by improving the delivery and financing of tuberculosis services and strengthening social protection for tuberculosis patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.